Pedrazzoli P, Gibelli N, Poggi G, Zambelli A, Saverio F, Della Cuna R, Locatelli F, Zibera C
Divisione di Oncologia Medica, IRCCS Fondazione Clinica del Lavoro, Pavia, Italy.
Anticancer Res. 1995 Jan-Feb;15(1):25-8.
Hematopoietic growth factors (HGFs) are glycoproteins that control hemopoiesis. They have potential usefulness in a range of clinical conditions including the treatment of patients with myelosuppression induced by chemotherapy. Among HGFs, Stem Cell Factor (SCF) and Interleukin 6 (IL-6) are attracting interest for their capacity to stimulate early hematopoietic progenitors. Furthermore, their use in combination with late-acting growth factors with a more lineage-restricted potential (such as granulocyte colony-stimulating factor, G-CSF) might be expected to offer optimal marrow stimulation and usefulness in clinical oncology. Since non-hematopoietic malignant cells may express receptors for HGFs and respond to these peptides in vitro, we investigated clonal growth 3H-thymidine incorporation and cell cycle analysis by flow cytometry of 5 human solid tumor cell lines under the influence of SCF and IL-6 with or without G-CSF. Our experiments show that these cytokines have no effects on the proliferative capacity of the cell lines tested. Based on our and previously reported data, the use of these HGFs can be considered safe in cancer patients.
造血生长因子（HGFs）是控制造血作用的糖蛋白。它们在一系列临床病症中具有潜在用途，包括治疗化疗引起的骨髓抑制患者。在造血生长因子中，干细胞因子（SCF）和白细胞介素6（IL-6）因其刺激早期造血祖细胞的能力而受到关注。此外，预计将它们与具有更多谱系限制潜力的后期作用生长因子（如粒细胞集落刺激因子，G-CSF）联合使用，可能会在临床肿瘤学中提供最佳的骨髓刺激和效用。由于非造血恶性细胞可能表达造血生长因子的受体并在体外对这些肽产生反应，我们通过流式细胞术研究了在有或没有G-CSF的情况下，SCF和IL-6影响下5种人类实体瘤细胞系的克隆生长、3H-胸腺嘧啶核苷掺入和细胞周期分析。我们的实验表明，这些细胞因子对所测试细胞系的增殖能力没有影响。根据我们和先前报道的数据，在癌症患者中使用这些造血生长因子可被认为是安全的。
